Since ER, PR, HER-2 and Ki67 are all cost effective laboratory tests that can be performed in most pathology laboratories, the investigation of additional protein-based tissue biomarkers that are useful in risk of recurrence prediction is important to improve the clinical management of breast cancer patients. This evidence concerns the gene PGR and breast carcinoma.